IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Purchases 33,013 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 33,013 shares of the stock in a transaction dated Tuesday, January 27th. The shares were bought at an average cost of $1.48 per share, for a total transaction of $48,859.24. Following the acquisition, the insider owned 1,034,312 shares in the company, valued at $1,530,781.76. The trade was a 3.30% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Stock Performance

Shares of IRIX stock opened at $0.90 on Friday. The stock’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $0.95. IRIDEX Corporation has a twelve month low of $0.61 and a twelve month high of $1.65. The company has a market capitalization of $15.78 million, a price-to-earnings ratio of -4.49 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. On average, analysts forecast that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On IRIDEX

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its position in IRIDEX by 6.7% during the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after acquiring an additional 25,067 shares during the period. Weber Capital Management LLC ADV bought a new stake in IRIDEX in the 2nd quarter valued at $206,616. Perkins Capital Management Inc. boosted its holdings in IRIDEX by 33.9% in the 1st quarter. Perkins Capital Management Inc. now owns 55,300 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 14,000 shares during the period. Thompson Davis & CO. Inc. grew its position in IRIDEX by 66.5% in the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 18,944 shares during the last quarter. Finally, United Capital Financial Advisors LLC acquired a new stake in IRIDEX in the 2nd quarter worth $41,000. Institutional investors and hedge funds own 20.10% of the company’s stock.

Key Headlines Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, IRIDEX currently has a consensus rating of “Hold” and a consensus price target of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.